ReviewVaccines2022
COVID-19 Vaccines and Autoimmune Hematologic Disorders.
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- ABO Discrepancy in Multiple Myeloma Initially Suspected as a Complication of COVID-19 Vaccination.Cureus · 2026Article
- Autoimmune Features of Post-COVID-19 Vaccination Syndrome and Their Impacts on the Renin-Angiotensin System.Vaccines · 2026Review
- Hematologic and coagulation responses to Johnson & Johnson COVID-19 vaccination in the Amhara region, Ethiopia.Scientific reports · 2026Article
- Evans Syndrome and COVID-19 Infection or Vaccination: A Systematic Review of Case Reports.Journal of hematology · 2025Review
- Unexpected hypereosinophilia after Sinopharm vaccination: a case report.BMC infectious diseases · 2025Article
- Cardiovascular Sequelae of the COVID-19 Vaccines.Cureus · 2025Review
- COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province.EXCLI journal · 2025Article
- Comparative immunologic profiling of mRNA and protein-conjugated vaccines: acute inflammatory responses and anti-PEG antibody production.Animal cells and systems · 2025Article
- Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study.Biomedicines · 2024Article
- The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement.Journal of clinical medicine · 2024Article
- Article
- Aplastic Anemia Following COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series.International journal of hematology-oncology and stem cell research · 2024Review
- TAFRO Syndrome and COVID-19.Biomedicines · 2024Review
- Antibodies against Platelet Glycoproteins in Clinically Suspected VITT Patients.Antibodies (Basel, Switzerland) · 2024Article
- Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study.Blood advances · 2024Article
- The mRNA-LNP vaccines - the good, the bad and the ugly?Frontiers in immunology · 2024Review
- Article
- Immune thrombocytopenic purpura in an elderly patient with cerebral hemorrhage after the fourth mRNA-1273 COVID-19 vaccination.Geriatrics & gerontology international · 2023Article
- Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination.Diabetology international · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally understood, although mimicry between viral and self-antigens plays a relevant role. It is important to remark that, although the incidence of these AEs is extremely low, their evolution may lead to life-threatening scenarios if treatment is not readily initiated. Hematologic autoimmune AEs have been associated with both mRNA and adenoviral vector-based SARS-CoV-2 vaccines. The main reported entities are secondary immune thrombocytopenia, immune thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, Evans syndrome, and a newly described disorder, so-called vaccine-induced immune thrombotic thrombocytopenia (VITT). The hallmark of VITT is the presence of anti-platelet factor 4 autoantibodies able to trigger platelet activation. Patients with VITT present with thrombocytopenia and may develop thrombosis in unusual locations such as cerebral beds. The management of hematologic autoimmune AEs does not differ significantly from that of these disorders in a non-vaccine context, thus addressing autoantibody production and bleeding/thromboembolic risk. This means that clinicians must be aware of their distinctive signs in order to diagnose them and initiate treatment as soon as possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.